8 Results for "

platinum(IV) complex

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "platinum(IV) complex" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-W007712
CAS No.: 3430-17-9
Synonyms: 2-Bromo-3-picoline
2-Bromo-3-methylpyridine (2-Bromo-3-picoline) is a heterocyclic intermediate of the halomethylpyridine family. 2-Bromo-3-methylpyridine can be used in the synthesis of platinum(IV) diazide complexes .
loading...
    loading...
Cat. No.: HY-W010062
CAS No.: 1878-66-6
4-Chlorophenylacetic acid is an aromatase antagonist. 4-Chlorophenylacetic acid inhibits estrogen-induced breast tumorigenesis by blocking estrogen conversion. 4-Chlorophenylacetic acid also serves as the sole carbon and energy source for Pseudomonas sp. CBS3; it is degraded via dechlorination and aromatic ring cleavage pathways, and induces the synthesis of protocatechuate 2,3-dioxygenase. 4-Chlorophenylacetic acid can be applied to studies related to estrogen-induced breast tumors and bacterial degradation pathways .
loading...
    loading...
Cat. No.: HY-179392
Research Areas:  

Cancer

Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Pt(IV) prodrug based on Cisplatin (HY-17394), and this design aims to enable Pt(IV) to be reduced to active Pt(II) under intracellular reducing conditions, while simultaneously releasing a derivative of Sunitinib (HY-10255A) with tyrosine kinase inhibitor (TKI) activity. Sunitinib-platinum(IV) prodrug-1 exhibits excellent cytotoxicity against renal cell carcinoma (RCC), causing DNA crosslinking and apoptosis. Sunitinib-platinum(IV) prodrug-1 inhibits the VEGFR/PDGFR signaling pathway, suppressing tumor growth and angiogenesis. Sunitinib-platinum(IV) prodrug-1 can be used for research on renal cell carcinoma .
loading...
    loading...
Cat. No.: HY-179418
Target:  

Apoptosis

Research Areas:  

Cancer

Ceritinib-platinum(IV)-4-phenylbutyrate (complex 7) is a Ceritinib (HY-15656)-conjugated Platinum(IV) prodrug with anticancer activity. Ceritinib-platinum(IV)-4-phenylbutyrate induces S-phase arrest, DNA damage responses, and apoptosis. Ceritinib-platinum(IV)-4-phenylbutyrate combines cytotoxicity with immune and anti-invasive activation in cancer cell models. Ceritinib-platinum(IV)-4-phenylbutyrate can be used for cancer research, such as non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-155807
CAS No.: 2668267-47-6
Target:  

STAT JAK Apoptosis

Research Areas:  

Cancer

DPP is a Platinum(IV) complex, bearing pterostilbene-derived axial ligand. DPP inhibit the JAK2-STAT3 pathway in breast cancer (BC) cells with antiproliferative activity, and activates caspase-3 and cleaved poly ADP-ribose polymerase to induces apoptosis. DPP promotes the maturation and antigen presentation of dendritic cells, and exhibits in vivo safety .
loading...
    loading...
Cat. No.: HY-155808
CAS No.: 2668267-41-0
Target:  

STAT JAK Apoptosis COX

Research Areas:  

Cancer

STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.
loading...
    loading...
Cat. No.: HY-W010062R
CAS No.: 1878-66-6
4-Chlorophenylacetic acid (Standard) is the analytical standard of 4-Chlorophenylacetic acid (HY-W010062). This product is intended for research and analytical applications. 4-Chlorophenylacetic acid is an aromatase antagonist. 4-Chlorophenylacetic acid inhibits estrogen-induced breast tumorigenesis by blocking estrogen conversion. 4-Chlorophenylacetic acid also serves as the sole carbon and energy source for Pseudomonas sp. CBS3; it is degraded via dechlorination and aromatic ring cleavage pathways, and induces the synthesis of protocatechuate 2,3-dioxygenase. 4-Chlorophenylacetic acid can be applied to studies related to estrogen-induced breast tumors and bacterial degradation pathways .
loading...
    loading...
Cat. No.: HY-182067
Research Areas:  

Cancer

anti-TNBC agent-15 is a platinum (IV) complex with anti-triple-negative breast cancer activity. anti-TNBC agent-15 inhibits cancer cell viability. anti-TNBC agent-15 reverses the resistance of triple-negative breast cancer cells to Cisplatin (HY-17394), increases intracellular uptake, and effectively triggers apoptosis by inducing DNA damage, enhancing intracellular ROS accumulation and activating the mitochondrial pathway. anti-TNBC agent-15 enhances lipid peroxidation, interferes with the signal transduction of the cystine/glutamate transporter-glutathione peroxidase axis, and induces ferroptosis. anti-TNBC agent-15 significantly inhibits tumor growth in triple-negative breast cancer/Cisplatin xenograft models. anti-TNBC agent-15 can be used for the research of triple-negative breast cancer .
loading...
    loading...